BARCELONA, Spain--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced that Germans Trias i Pujol, a pioneering hospital serving more than 800,000 people in north Barcelona, Spain, is launching a breakthrough telehealth and remote patient management initiative using Masimo technology. The SESHAT project is focused on using advanced wearable technologies and wireless connectivity to allow remote clinicians to keep track of patients’ physiological data in near real time wherever they are, whether the patient is in another part of the hospital or at home.

西班牙巴塞罗那--（商业新闻短讯）--Masimo（纳斯达克：MASI）今天宣布，德国Trias i Pujol是一家领先的医院，在西班牙巴塞罗那北部为80多万人提供服务，正在使用Masimo技术启动一项突破性的远程医疗和远程患者管理计划。SESHAT项目的重点是使用先进的可穿戴技术和无线连接，使远程临床医生无论身在何处，无论患者是在医院的另一部分还是在家中，都能近乎实时地跟踪患者的生理数据。

The project, which began in the fourth quarter of 2023 and is slated to last at least three years, includes the implementation of up to 1,000 Masimo W1® medical watches, 100 Radius VSM™ Wearable Continuous Vital Signs Monitors, 10 Patient SafetyNet™ Systems, and a host of additional Masimo Hospital Automation™ products..

该项目始于2023年第四季度，预计将持续至少三年，包括实施多达1000只Masimo W1®医疗手表、100只Radius VSM™可穿戴式连续生命体征监护仪、10个Patient SafetyNet™系统以及许多其他Masimo Hospital Automation™产品。。

Joe Kiani, Founder and CEO of Masimo, said, “We are honored to partner with Germans Trias i Pujol to support the SESHAT project. When I founded Masimo 35 years ago, our mission was to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications.

Masimo创始人兼首席执行官乔·基亚尼（JoeKiani）表示：“我们很荣幸能与德国Trias i Pujol合作，支持SESHAT项目。35年前，我成立Masimo时，我们的使命是通过对新网站和应用程序进行无创监测，改善患者预后，降低护理成本。

Now, with decades of innovation and refinement, we are bringing our pioneering accurate and continuous monitoring technologies to even more new sites and applications, including the home – with powerful wearable, tetherless, and remote modalities like Masimo SET®-based Masimo W1 and Radius VSM. Our breakthrough predictive algorithm Halo™, AI-powered tools, and connectivity and automation solutions in turn make that accurate, precise, rich stream of actionable patient data available to clinicians when and where they need it, helping patients feel connected and cared for, and informing evermore insightful decisions about care.

现在，经过数十年的创新和改进，我们正在将我们开创性的精确和连续监测技术带到更多的新网站和应用程序，包括家庭-功能强大的可穿戴、无系带和远程模式，如基于Masimo SET®的Masimo W1和Radius VSM。我们突破性的预测算法Halo™、人工智能工具以及连通性和自动化解决方案反过来又使临床医生在需要时随时随地可以获得准确、精确、丰富的可操作患者数据流，帮助患者感受到连接和关怀，并为更多有见地的护理决策提供信息。

Ultimately, we believe this will improve outcomes while reducing the cost of care, in keeping with our founding mission. We look forward to gleaning innumerable insights and improving 800,000 lives with the forward-thinking clinicians of Germans Trias i Pujol.”.

最终，我们相信这将改善结果，同时降低护理成本，符合我们的创始使命。我们期待着与德国人Trias i Pujol的前瞻性临床医生一起收集无数的见解，改善80万人的生活。”。

Dr. Oriol Estrada, Director of Healthcare Strategy and Innovation at Germans Trias, commented, “Project SESHAT, named for the Egyptian goddess of writing and measurement, aims to transform healthcare from a reactive to a predictive model thanks to continuous and real-time reliable patient data measured through wearable technology, both in hospital and at home.”.

Germans Trias医疗保健战略和创新总监Oriol Estrada博士评论道：“SESHAT项目以埃及书写和测量女神命名，旨在将医疗保健从被动模式转变为预测模式，这要归功于通过可穿戴技术在医院和家中测量的连续实时可靠的患者数据。”。

The SESHAT project arose from needs identified during the COVID pandemic and centers on the remote monitoring of patients with complex care requirements. The project's goal is to obtain real-time physiological data from patients and have that data help clinicians improve health outcomes. By facilitating better tracking of each patient’s physiological changes, and combining such changes with other available health data, SESHAT project clinicians hope to design and validate better prospective indicators of clinical progress and therapeutic adherence.

SESHAT项目产生于新型冠状病毒大流行期间确定的需求，并以远程监测具有复杂护理需求的患者为中心。该项目的目标是从患者那里获得实时生理数据，并让这些数据帮助临床医生改善健康状况。通过更好地跟踪每位患者的生理变化，并将这些变化与其他可用的健康数据相结合，SESHAT项目临床医生希望设计和验证更好的临床进展和治疗依从性前瞻性指标。

Their goal is ultimately to help institutions transition from a reactive care model, in which healthcare teams treat symptomatic diseases, to a more proactive model in which teams receive information that enables them to anticipate complications or select more suitable medications to ensure a better therapeutic response, based on each patient's profile..

他们的目标最终是帮助机构从医疗团队治疗症状性疾病的反应式护理模式转变为更积极主动的模式，在这种模式中，团队可以根据每个患者的情况接收信息，使他们能够预测并发症或选择更合适的药物，以确保更好的治疗反应。。

“To achieve these objectives,” continued Dr. Estrada, “wearable technology that is robust, reliable, and does not hinder the patient's normal life had to be selected. After analyzing various options, Masimo technology embedded in medical-grade wearable devices such as Masimo W1 and Radius VSM was chosen.

“为了实现这些目标，”埃斯特拉达博士继续说道，“必须选择健壮、可靠且不妨碍患者正常生活的可穿戴技术。在分析了各种选择后，选择了嵌入医疗级可穿戴设备（如Masimo W1和Radius VSM）中的Masimo技术。

A decisive factor in this choice was Masimo's willingness to become a technological partner beyond just being a technology provider. We have established a strategic collaboration whereby the SESHAT project will serve as a validation field for technological improvements and identification of new needs in which both institutions will cooperate.

这一选择的一个决定性因素是Masimo愿意成为技术合作伙伴，而不仅仅是技术提供商。我们已经建立了战略合作关系，SESHAT项目将作为技术改进和确定新需求的验证领域，这两个机构将在其中进行合作。

When deciding, it was important for the project leaders to work with a leading company in the monitoring technology sector that offers a portfolio with a global solution for all phases of patient care: from the hospital to the home, while also providing integration with Hospital Information Systems.”.

在做出决定时，项目负责人必须与监测技术领域的领先公司合作，该公司为患者护理的所有阶段提供全球解决方案：从医院到家庭，同时还提供与医院信息系统的集成。”。

The Germans Trias i Pujol University Hospital of Badalona belongs to the Catalan Health Institute. It is a high-tech center that provides health services to a population of 800,000 inhabitants in the North Metropolitan area of Barcelona. Since its foundation, the hospital has been a pioneer in the development and care in various areas of excellence, such as infectious, cardiovascular, inflammatory, oncological, and respiratory diseases, among others.

巴达洛纳的德国Trias i Pujol大学医院隶属于加泰罗尼亚健康研究所。这是一个高科技中心，为巴塞罗那北部都市区80万居民提供医疗服务。自成立以来，该医院一直是传染病，心血管病，炎症，肿瘤和呼吸系统疾病等各个卓越领域发展和护理的先驱。

It encompasses a powerful biomedical research campus with 12 internationally renowned institutions, employing over 6,000 professionals and researchers in the field of health. Clinical innovation—transforming clinical problems into opportunities for improving outcomes—is one of the institution's strategic pillars..

它包括一个强大的生物医学研究校园，拥有12个国际知名机构，雇用了6000多名卫生领域的专业人员和研究人员。临床创新将临床问题转化为改善结果的机会是该机构的战略支柱之一。。

Halo is not FDA cleared and is not available in the U.S.

Halo未经FDA批准，在美国不可用。

@Masimo | #Masimo

@Masimo.#Masimo

About Masimo

关于Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio.

Masimo（纳斯达克股票代码：MASI）是一家全球医疗技术公司，开发和生产多种行业领先的监测技术，包括创新测量、传感器、患者监护仪以及自动化和连接解决方案。此外，Masimo Consumer Audio拥有八个传奇音频品牌，包括Bowers&Wilkins、Denon、Marantz和Polk Audio。

Our mission is to improve life, improve patient outcomes, and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.1 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,2 improve CCHD screening in newborns3 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.4-7 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,8 and is the primary pulse oximetry at 9 of the top 10 hospitals as ranked in the 2022-23 U.S.

我们的使命是改善生活，改善患者预后，降低护理成本。1995年推出的Masimo SET®运动测量和低灌注™脉搏血氧仪已在100多项独立和客观的研究中显示，其性能优于其他脉搏血氧仪技术。1 Masimo SET®还被证明可以帮助临床医生减少新生儿严重的早产儿视网膜病变，2改善新生儿的CCHD筛查3，并且在手术后病房使用Masimo Patient SafetyNet™进行连续监测时，可以减少快速反应团队的激活，ICU的转移和成本。4-7 Masimo SET®估计可用于全球领先医院和其他医疗机构的2亿多患者，8是前10名患者中9名的主要脉搏血氧仪2022-23年美国排名的医院。

News and World Report Best Hospitals Honor Roll.9 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™).

新闻和世界报道最佳医院荣誉榜。9 2005年，Masimo引入了rainbow®脉搏CO血氧测定技术，可以无创和连续监测以前只能有创测量的血液成分，包括总血红蛋白（SpHb®），氧含量（SpOC™），碳氧合血红蛋白（SpCO®），高铁血红蛋白（SpMet®），Pleth变异指数（PVi®），RPVi™（rainbow®PVi）和氧储备指数（ORi™）。

In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possibl.

2013年，Masimo推出了Root®患者监测和连接平台，该平台从头开始构建，尽可能灵活和可扩展。

RPVi has not received FDA 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

RPVi尚未获得FDA 510（k）许可，也无法在美国销售。商标Patient SafetyNet的使用已获得大学健康系统联盟（University HealthSystem Consortium）的许可。

References

参考文献

Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.

已发表的脉搏血氧仪临床研究和Masimo SET®的益处可在我们的网站上找到http://www.masimo.com.比较研究包括独立和客观的研究，这些研究由科学会议上发表的摘要和同行评审的期刊文章组成。

Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.

Castillo A等人。通过改变临床实践和SpO2技术预防早产儿视网膜病变。儿科学报。2011年2月；100（2）：188-92。

de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.

de Wahl-Granelli A等人。脉搏血氧仪筛查对导管依赖性先天性心脏病检测的影响：一项针对39821名新生儿的瑞典前瞻性筛查研究。英国医学杂志。2009年；1月8日；338

Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.

Taenzer A等人。脉搏血氧仪监测对救援事件和重症监护病房转移的影响：前后并发研究。麻醉学。2010:112（2）：282-287。

Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.

Taenzer A等人。术后监测-达特茅斯经验。麻醉患者安全基金会新闻稿。2012年春夏。

McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.

McGrath S等人。普通护理病房的监测管理：策略，设计和实施。质量和患者安全联合委员会杂志。2016年7月；42（7）：293-302。

McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.

McGrath S等人。与镇静和镇痛药物相关的住院呼吸骤停：持续监测对患者死亡率和严重发病率的影响。J患者Saf。2020年3月14日DOI:10.1097/PTS.0000000000000696。

Estimate: Masimo data on file.

估计：Masimo数据存档。

http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.

Forward-Looking Statements

前瞻性声明

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo W1™, Radius VSM™, Hospital Automation™, SET®, the partnership of Masimo and Germans Trias i Pujol Hospital (the “Partnership”), and the prospect of SESHAT project.

本新闻稿包括1933年《证券法》第27A节和1934年《证券交易法》第21E节中定义的与1995年《私人证券诉讼改革法》相关的前瞻性声明。这些前瞻性声明包括关于Masimo W1™、Radius VSM™、Hospital Automation™、SET®、Masimo和Germans Trias i Pujol Hospital的合作关系（“合作关系”）的潜在有效性的声明，以及SESHAT项目的前景。

These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo W1, Radius VSM, Hospital Automation, and SET®, as well as the Partnership and the SESHAT project ,contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to the assumption that the SESHAT project will last at least three years; risks related to COVID-19; as well as other factors discussed in the 'Risk Factors' section of our most recent reports filed with the Securities and Exchange Commission ('SEC'), which may be obtained for free at the SEC's website at www.sec.gov.

这些前瞻性陈述基于对影响我们的未来事件的当前预期，并受到风险和不确定性的影响，所有这些都难以预测，其中许多超出了我们的控制范围，并且由于各种风险因素，可能导致我们的实际结果与我们的前瞻性陈述中表达的结果存在重大不利差异，包括但不限于：与我们关于临床结果可重复性的假设相关的风险；与我们相信Masimo独特的无创测量技术（包括Masimo W1，Radius VSM，Hospital Automation和SET®）以及Partnership和SESHAT项目）有助于积极的临床结果和患者安全相关的风险；与我们相信Masimo非侵入性医疗突破提供成本效益高的解决方案和独特优势有关的风险；与假设SESHAT项目将持续至少三年有关的风险；与新型冠状病毒相关的风险；以及我们向美国证券交易委员会（“SEC”）提交的最新报告中“风险因素”部分讨论的其他因素，这些报告可以在SEC的网站www.SEC.gov上免费获得。

Although we believe that the expectations reflected in o.

虽然我们相信o中反映的期望。